arXiv:2608. 05761v1 Announce Type: new Abstract: The development of nanotherapeutics often involves extensive empirical optimization due to the sensitivity of nanoparticle properties, such as size and polydispersity index (PDI), to minor changes in process parameters.
By Kai Dahms, Eilien Heinrich, Jochen Schmid, Michael Bortz, Iryna Savych, Regina Bleul
The study presents an interpretable machine‑learning framework that predicts whether lipid nanoparticles (LNPs) accumulate in the liver or in extrahepatic tissues after intravenous injection. Using a curated dataset of 476 LNP formulations, the authors engineered 808 features from lipid chemistry and formulation composition, and achieved ROC‑AUC scores up to 0.874 with tree‑based models. SHAP analysis identified ionizable‑lipid descriptors and formulation fractions—especially ionizable lipid, sterol, and PEGylated/polymer‑conjugated lipid components—as key drivers of biodistribution, offering actionable design principles for targeting tissues beyond the liver.
By Asal Mehradfar, Mohammad Shahab Sepehri, Owen Antholine, Varun Shankar, Glen S. Kwon, Salman Avestimehr, Morteza Rasoulianboroujeni
arXiv:2507. 03209v2 Announce Type: replace-cross Abstract: The discovery of new ionizable lipids for efficient lipid nanoparticle (LNP)-mediated RNA delivery remains a major bottleneck in RNA therapeutics development.
By Asal Mehradfar, Mohammad Shahab Sepehri, Jose Miguel Hernandez-Lobato, Glen S. Kwon, Mahdi Soltanolkotabi, Salman Avestimehr, Morteza Rasoulianboroujeni
Co-Scientist unites Boston Children’s Hospital and MIT’s labs to explore new RNA-based treatments for ALS.
Scientists are using AlphaFold to strengthen a photosynthesis enzyme for resilient, heat-tolerant crops.
arXiv:2505.23862v2 Announce Type: replace-cross
Abstract: The mRNA optimization is essential for mRNA vaccines, therapies, and industrial protein production. Based on current explorations, an ideal o...
By Zheng Gong, Ziyi Jiang, Weihao Gao, Yuanyuan Wang, Zhining Cai, Deng Zhuo, Lan Ma